JP2025098167A5 - - Google Patents

Info

Publication number
JP2025098167A5
JP2025098167A5 JP2025051382A JP2025051382A JP2025098167A5 JP 2025098167 A5 JP2025098167 A5 JP 2025098167A5 JP 2025051382 A JP2025051382 A JP 2025051382A JP 2025051382 A JP2025051382 A JP 2025051382A JP 2025098167 A5 JP2025098167 A5 JP 2025098167A5
Authority
JP
Japan
Prior art keywords
amino acid
acid position
fcrn antagonist
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025051382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025098167A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/043533 external-priority patent/WO2021016571A2/en
Application filed filed Critical
Publication of JP2025098167A publication Critical patent/JP2025098167A/ja
Publication of JP2025098167A5 publication Critical patent/JP2025098167A5/ja
Pending legal-status Critical Current

Links

JP2025051382A 2019-07-25 2025-03-26 Fcrnアンタゴニストで抗体媒介性障害を処置する方法 Pending JP2025098167A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
US62/878,541 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists
JP2022504569A JP2022542884A (ja) 2019-07-25 2020-07-24 Fcrnアンタゴニストで抗体媒介性障害を処置する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022504569A Division JP2022542884A (ja) 2019-07-25 2020-07-24 Fcrnアンタゴニストで抗体媒介性障害を処置する方法

Publications (2)

Publication Number Publication Date
JP2025098167A JP2025098167A (ja) 2025-07-01
JP2025098167A5 true JP2025098167A5 (cg-RX-API-DMAC7.html) 2026-01-08

Family

ID=72087159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504569A Pending JP2022542884A (ja) 2019-07-25 2020-07-24 Fcrnアンタゴニストで抗体媒介性障害を処置する方法
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Fcrnアンタゴニストで抗体媒介性障害を処置する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022504569A Pending JP2022542884A (ja) 2019-07-25 2020-07-24 Fcrnアンタゴニストで抗体媒介性障害を処置する方法

Country Status (13)

Country Link
US (1) US12655200B2 (cg-RX-API-DMAC7.html)
EP (1) EP4004039A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022542884A (cg-RX-API-DMAC7.html)
KR (1) KR20220038432A (cg-RX-API-DMAC7.html)
CN (2) CN114466663B (cg-RX-API-DMAC7.html)
AU (1) AU2020315925A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001255A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148764A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001164A2 (cg-RX-API-DMAC7.html)
IL (1) IL290101A (cg-RX-API-DMAC7.html)
MX (1) MX2022001038A (cg-RX-API-DMAC7.html)
TW (1) TW202120539A (cg-RX-API-DMAC7.html)
WO (1) WO2021016571A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
TW202525845A (zh) 2023-08-23 2025-07-01 法商賽諾菲公司 基於ctla—4之溶體降解劑及其用途
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
IL328245A (en) 2023-11-08 2026-07-01 Sanofi Sa CD25-based lysosomal compartment and its uses
AU2024413168A1 (en) * 2023-12-27 2026-07-16 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE
WO2026133288A2 (en) 2024-12-20 2026-06-25 Sanofi IL-2RβΥ BASED LYSOSOMAL DEGRADER AND USES THEREOF
WO2026133294A1 (en) 2024-12-20 2026-06-25 Sanofi Pd-1/gitr multispecific binding polypeptides and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション,インコーポレイテッド Fc領域変異体
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US9200079B2 (en) * 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
ES2573642T3 (es) 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX2013011366A (es) * 2011-03-30 2014-05-12 Chugai Pharmaceutical Co Ltd Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad.
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
US20170211876A1 (en) 2014-06-12 2017-07-27 Hoffmann-La Roche Inc. Method for selecting antibodies with modified fcrn interaction
RU2713131C1 (ru) 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
MX386491B (es) * 2015-03-09 2025-03-18 argenx BV Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
CA3022547A1 (en) 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
WO2018213097A1 (en) * 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020015006A2 (pt) * 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada

Similar Documents

Publication Publication Date Title
JP2022542884A5 (cg-RX-API-DMAC7.html)
JP2024026255A5 (cg-RX-API-DMAC7.html)
JP7116736B2 (ja) 操作されたヘテロ二量体タンパク質
JP6334669B2 (ja) 改善された半減期を有する修飾された抗体
JP2021511830A5 (cg-RX-API-DMAC7.html)
CA2684626C (en) Penta-specific antibodies binding il-8, gro-alpha, gro-beta, gro-gamma and ena-78
JP2012516158A5 (cg-RX-API-DMAC7.html)
JP2019504617A5 (cg-RX-API-DMAC7.html)
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2025522482A (ja) インターロイキン13に結合する抗体及び使用方法
HRP20171080T1 (hr) Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
RU2016139006A (ru) Мультимерные fc-белки
JP2020520231A5 (cg-RX-API-DMAC7.html)
MX2011001909A (es) Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos.
US20180215805A1 (en) Therapeutic and diagnostic agents
JP2022542884A (ja) Fcrnアンタゴニストで抗体媒介性障害を処置する方法
JP2025126239A5 (cg-RX-API-DMAC7.html)
CN103459427A (zh) 针对人IgG抗体的CH1结构域中表位的抗原结合蛋白
CN116113642A (zh) 多特异性抗体、包含其的组合物、及其载体和用途
CA3011784A1 (en) Anti-tnf.alpha.-antibodies and functional fragments thereof
RU2019123112A (ru) Анти-il-5 антитела
JP2025026957A (ja) IL-1β受容体シグナル伝達に干渉する剤
JP2025517120A5 (cg-RX-API-DMAC7.html)